For instance: FOXO1 is downregulated in CML but shows no significant change in AML or CLL, unlike previous pan-cancer autophagy markers (e.g., BECN1) that lack disease specificity (7). This evidence concerns the gene FOXO1 and chronic myelogenous leukemia, BCR-ABL1 positive.